期刊文献+

The Mechanism of Panax Notoginseng in the Treatment of Heart Failure Based on Biological Analysis

原文传递
导出
摘要 Objective:This study aimed to explore the mechanism of Panax notoginseng(PNS)in the treatment of heart failure(HF)based on network pharmacology analysis combined with experimental verification.Materials and Methods:The potential targets and key pathways of effective components of PNS in the treatment of HF were revealed using network pharmacology.The postacute myocardial infarction(MI)HF rat model was established by ligating the left anterior descending branch of the coronary artery.The rats were divided into three groups:model,PNS,and fenofibrate groups.PNS(0.75 g/kg)and fenofibrate(10 mg/kg)were administered for 28 days.The efficacy and target mechanism of PNS in the treatment of HF were verified by cardiac ultrasound,Masson staining,and western blotting(WB)techniques.Results:The results of network pharmacology showed that seven potentially active compounds,such as quercetin,were obtained,involving 105 targets of HF;GO function was enriched to 1240 items;and KEGG enrichment covered 1240 signal pathways.The results of echocardiography showed that EF and FS of HF rats after MI were significantly increased,while Left ventricular internal dimension diastole(LVIDd)and Left ventricular internal dimension systole(LVIDs)were significantly decreased(P<0.001,P<0.05).Masson staining showed that PNS could reduce the degree of myocardial fibrosis(MF)in HF.The results of WB showed that PNS could reduce the expression of the p-p38-MAPK,transforming growth factor-beta(TGF-β),and Smad3 in HF rats.Conclusion:PNS inhibited MF and treated HF by regulating p-p38 MAPK-TGF-βpathway,which lays a theoretical foundation for further study of its pharmacological mechanism and key target.
出处 《World Journal of Traditional Chinese Medicine》 CAS 2022年第4期530-538,共9页 世界中医药杂志(英文)
基金 supported by the National Natural Science Foundation of China(grant number 81822049) the Major New Drug Creation of the Ministry of Science and Technology(grant number 2019ZX09201004-001-011)。
  • 相关文献

参考文献9

二级参考文献98

  • 1王岱岱,姚震,钟江华,顾申红,陈淑芬,张光星,陈跃武.急性心肌梗死患者Killip心功能分级与血浆促心肌素-1浓度变化的关系[J].岭南心血管病杂志,2009,15(5):354-356. 被引量:11
  • 2Poay Sian Sabrina Lee,Kian Keong Poh.Endothelial progenitor cells in cardiovascular diseases[J].World Journal of Stem Cells,2014,6(3):355-366. 被引量:22
  • 3国家中医药管理局医政司胸痹急症协作组东北分组.胸痹心厥(冠心病心肌梗塞)急症诊疗规范[J].中国中医急症,1995,4(4):183-185. 被引量:95
  • 4杨俊荣,敬松,李志宏,秦海林.新疆阿魏化学成分研究[J].中国中药杂志,2007,32(22):2382-2384. 被引量:18
  • 5Segura A M, Frazier O H, Buja L M. Fibrosis and heart failure [J]. Heart Fail Rev,2014,19(2):173.
  • 6Porter K E, Turner N A. Cardiac fibrablasts : at the heart of myo- cardial remodeling[ J ]. Pharmacol Ther,2009, 123 (2) :255.
  • 7Yuan S M, Jing H. Cardiac pathologies in relation to Smad-de- pendent pathways [ J ]. Interact Cardiovasc Thorac Surg, 2010,11 (4) : 455.
  • 8E1-Sheakh A R, Ghoneim H A, Suddek G M. Attenuation of oxi- dative stress, inflammation, and endothelial dysfunction in hyper- cholesterolemic rabbits by allicin[ J]. Can J Physiol Pharmacol, 2015, 14:1.
  • 9Kaga S, Zhan L, Matsumoto M, et al. Resveratrol enhances neo- vaseularization in the infarcted rat myocardium through the indue-tion of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor[ J]. J Mol Cell Cardiol, 2005, 39:813.
  • 10Penumathsa S V, Thirunavukkarasu M, Koneru S, et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat [ J ]. J Mol Cell Cardiol, 2007, 42:508.

共引文献296

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部